Whole brain radiation therapy for patients with brain metastases: survival outcomes and prognostic factors in a contemporary institutional series
Strahlentherapie und Onkologie · 2024-11 · 200 (11) · 942-948
DOI: 10.1007/s00066-024-02275-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Strahlentherapie und Onkologie, online erschienen am 12.08.2024. Verfasst von Anna Estermann und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Radiotherapy and Radiation Oncology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland. Hauptthemen laut MEDLINE: Brain Neoplasms, Cranial Irradiation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Basel.
Abstract (Originalsprache)
Purpose
To study survival outcomes and prognostic factors in patients undergoing whole brain radiation therapy (WBRT) for brain metastases in the contemporary setting.
Methods
Patients undergoing WBRT from 2013–2021 were retrospectively included in an ethics-approved institutional database. Patient and treatment characteristics were assessed, including patient age, primary tumor histology, Karnofsky Performance Status (KPS), extracranial disease, as well as WBRT dose. Overall survival (OS) was calculated from onset of WBRT using the Kaplan-Meier method.
Results
A total of 328 patients (median age 63 years) were included. Most patients (52%) had ≥ 10 brain metastases, and 17% had leptomeningeal disease. WBRT was delivered with 10 × 3 Gy (64%), 5 × 4 Gy (25%), or other regimens (11%). Median follow-up was 4.4 months (range, 0.1–154.3), and median OS was 4.7 months (95%CI, 3.8–6.0). OS differed between histologies ( p = 0.01), with the longest survival seen in breast cancer (median 7.7 months). Patients with KPS of 90–100 survived for a median of 8.3 months, compared to 4.1 months with KPS 70–80, and 1.7 months with KPS < 70 ( p < 0.01). Multivariate analyses revealed that KPS had the largest impact on survival. Patients who received a WBRT dose of ≥ 30 Gy also had a reduced risk of death (HR 0.45; p < 0.001). Survival differed between subgroups reclassified according to the Rades scoring system ( p < 0.01).
Conclusion
Survival outcomes of patients undergoing WBRT in the contemporary era appear comparable to historical cohorts, although individual patient factors need to be considered. Patients with otherwise favorable prognostic factors may benefit from longer-course WBRT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinic of Radiotherapy and Radiation Oncology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
- Clinic of Radiotherapy and Radiation Oncology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland. tobias.finazzi@usb.ch.
- Department of Radiation Oncology, Kantonsspital Baden, Baden, Switzerland. tobias.finazzi@usb.ch.
ORCID-Profile: Tobias Finazzi
Förderung
- University of Basel
Zitieren
APA
Estermann, A., Schneider, C., Zimmermann, F., Papachristofilou, A., & Finazzi, T. (2024). Whole brain radiation therapy for patients with brain metastases: survival outcomes and prognostic factors in a contemporary institutional series. Strahlentherapie und Onkologie, 200(11), 942-948. https://doi.org/10.1007/s00066-024-02275-x
Vancouver
Estermann A, Schneider C, Zimmermann F, Papachristofilou A, Finazzi T. Whole brain radiation therapy for patients with brain metastases: survival outcomes and prognostic factors in a contemporary institutional series. Strahlentherapie und Onkologie. 2024;200(11):942-948. doi:10.1007/s00066-024-02275-x
BibTeX
@article{Estermann2024,
author = {Estermann, Anna and Schneider, Chiara and Zimmermann, Frank and Papachristofilou, Alexandros and Finazzi, Tobias},
title = {Whole brain radiation therapy for patients with brain metastases: survival outcomes and prognostic factors in a contemporary institutional series},
journal = {Strahlentherapie und Onkologie},
year = {2024},
volume = {200},
number = {11},
pages = {942--948},
doi = {10.1007/s00066-024-02275-x}
}
EUVIMED